Tesamorelin Explained: Acylated GHRH (1-44) Chemistry, Mechanism and Research Use

Tesamorelin is a synthetic version of the complete 44-residue human growth hormone-releasing hormone, differing from the native peptide in one respect: a trans-3-hexenoyl group sits on its N-terminal tyrosine. This lipophilic cap is there to slow cleavage by dipeptidyl peptidase-4 without disturbing receptor binding. With a molar mass of 5135.86 g/mol it is the heaviest GHRH-family compound in our range, about 1.5 times the mass of sermorelin. It is also the only GHRH analogue listed here that has completed a full regulatory approval: tesamorelin acetate is an FDA-approved prescription drug sold as Egrifta, and that status governs how it should be discussed.

Below we look at the chemistry of the acyl cap, the receptor pharmacology, the clinical and preclinical literature and the practical handling of research material. The tesamorelin we supply is research-grade peptide intended solely for in-vitro and preclinical studies; it is not the licensed medicinal product.

Structure and origin: a single acyl group fixes a single weakness

Natural GHRH is a hypothalamic peptide of 44 residues whose main drawback as a drug is its N-terminal end. DPP-4 quickly removes the first two amino acids, and since that N-terminal stretch is precisely the part that docks into the receptor's transmembrane core, what remains is practically inactive. Every stabilised GHRH analogue exists to solve this one problem; they are distinguished chiefly by the solution they chose.

Sermorelin leaves the problem unsolved: it is plain GHRH (1–29) amide and disappears within minutes. Modified GRF 1-29, marketed as CJC-1295 without DAC, swaps the amino acid at position 2 so DPP-4 no longer recognises its cleavage site. Tesamorelin chooses a third strategy, keeping the sequence untouched but acylating the alpha-amino group of tyrosine 1 with a six-carbon unsaturated chain, trans-3-hexenoyl. Capping that amine removes the free N-terminus the enzyme needs, and the cap is compact enough not to interfere with receptor binding.

Keeping the whole 44-residue chain, instead of cutting it back to 1–29 like most analogues, is intentional. It makes synthesis longer and more costly and gives more residues that can degrade, but the sequence stays native from end to end.

Proposed mechanism of action

Pharmacologically, tesamorelin is a straightforward GHRH receptor agonist. On pituitary somatotrophs, receptor binding activates Gs, cyclic AMP rises and protein kinase A switches on, increasing both transcription and release of growth hormone. The hypothalamic-pituitary axis stays intact, so somatostatin continues to restrain secretion and IGF-1 feedback still operates; the result amplifies the existing pulsatile rhythm rather than replacing it. This is what separates a GHRH analogue from recombinant growth hormone, which sidesteps the axis completely and belongs to a distinct, prescription-only product class.

The downstream effects studied most closely involve fat tissue, in particular visceral adipose tissue, where growth hormone signalling is linked to lipolysis. Tesamorelin became a medicine precisely because visceral fat accumulation responded in a patient group for whom it was a recognised clinical problem.

Research to date

Clinical trials in humans

Unlike most peptides found in research catalogues, tesamorelin has a real phase 3 history. Randomised, placebo-controlled trials in people with HIV and lipodystrophy with excess visceral fat reported CT-measured reductions in visceral adipose tissue together with changes in lipid parameters and IGF-1. On the strength of these trials the FDA approved tesamorelin acetate in 2010 to reduce excess abdominal fat in HIV-associated lipodystrophy, and it remains available only on prescription. Subsequent investigator-initiated studies have explored other settings, including liver fat in HIV-associated fatty liver disease.

All of these results relate to an authorised pharmaceutical given under medical supervision. They say nothing about research-grade peptide, and none of that clinical evidence carries over to material sold for laboratory purposes.

Preclinical endocrinology

In cell and animal work tesamorelin serves as a stable and well-defined GHRH receptor agonist: a benchmark for shorter or less stable analogues, and a tool for studying prolonged receptor activation free of the minutes-long clearance of native GHRH.

Adipose tissue and metabolic models

Animal studies have looked at lipolysis, the distribution of fat depots and liver lipid handling, following up the clinical findings that drove the drug's development. That background is described in more depth in our longer article on the HIV lipodystrophy trials.

Combination studies

GHRH receptor agonists and growth hormone secretagogue receptor agonists act on the same somatotroph through different second-messenger routes, so pairing them is a common study design. Ready-blended research material, for example tesamorelin with ipamorelin, is available for this purpose; whether the combined signal exceeds simple addition is still unresolved in the literature.

Available formats and vial sizes

We stock research-grade tesamorelin as lyophilized powder in sealed vials of 5 mg (€85), 10 mg (€145) and 20 mg (€225). The molar numbers deserve attention: at 5135.86 g/mol, 5 mg corresponds to only about 0.97 micromoles, around two-thirds of the moles in a 5 mg sermorelin vial. Comparing GHRH analogues by mass therefore misleads, and structure-activity work should match them on a molar basis. The group is listed under GHRH analogs. The licensed prescription product appears separately as a prescription reference and is not sold as research material.

Reconstitution and storage in the lab

Worked calculation: dissolving a 10 mg vial in 2 mL of bacteriostatic water yields 5 mg/mL, i.e. 5,000 mcg/mL, so 0.1 mL (10 units on a U-100 syringe) holds 500 mcg. Expressed in molar terms, 5 mg/mL of a 5135.86 g/mol peptide is about 973 micromolar, just below 1 mM, which makes a handy starting point for serial dilution to the nanomolar range used in receptor assays.

Handle it as you would any long, partly hydrophobic peptide. Run the diluent slowly down the inside of the vial, swirl gently instead of shaking and wait for complete dissolution. The acyl chain raises surface activity, so agitation causes foaming and aggregation more readily than with short hydrophilic peptides. Its methionine residue oxidises easily, so keep stock solutions away from air and light. Store lyophilized vials at −20 °C or below and away from moisture; aliquot reconstituted material and keep it cold. More detail is available in the peptide storage guide.

Purity and interpreting the COA

Every lot is purified by reversed-phase HPLC to a minimum of 99%, identity-confirmed by mass and shipped with a lot-specific certificate. Two checks matter most for tesamorelin. The first is mass, because the acyl group defines the compound: the measured value should correspond to 5135.86 g/mol, whereas unmodified GHRH (1–44) would read about 96 Da lower. If the mass fits the non-acylated peptide, the material is not tesamorelin, regardless of its label. The second is chromatographic resolution, which counts for more at 44 residues than at 7 or 15. Single-residue deletion products are the typical impurity of long syntheses and may elute near the main peak, so a symmetrical, well-separated single peak is what backs up the purity figure. Our COA reading guide explains how to judge both points.

Regulatory position

Tesamorelin acetate is a prescription-only medicine that the FDA approved in 2010 for reducing excess abdominal fat in HIV-associated lipodystrophy. Such products are made to pharmaceutical standards, distributed through regulated channels and used under medical supervision. Trial results for the licensed product cannot be applied to research material, which is supplied for laboratory use only.

Related compounds and further reading

For a side-by-side look at structure and pharmacokinetics against the shortest family member, read tesamorelin vs sermorelin. Modified GRF 1-29 and CJC-1295 with DAC illustrate two other ways of stabilising a ligand for the same receptor, whereas ipamorelin and the GHRPs work through the growth hormone secretagogue receptor. For the wider picture, visit the growth hormone and IGF axis hub.